UNLABELLED: Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. Here we report that infection of hepatic cells by HCV stimulates nuclear factor kappa B (NFκB)-dependent production of thymic stromal lymphopoietin (TSLP). Hepatocyte-derived TSLP in turn conditions dendritic cells (DCs) to drive T-helper (Th)17 differentiation. The TSLP secreted by HCV-infected hepatoma cells is capable of activating human monocyte-derived DCs by up-regulating the expression of CD40, CD86, CCL17, CCL22, and CCL20 which are activating markers of DCs. In addition, the production of key cytokines for Th17 differentiation, transforming growth factor beta (TGF-β), interleukin (IL)-6, and IL-21, is enhanced by human monocytes upon coculture with HCV-infected cells. Importantly, the blockade of TSLP using neutralizing antibody prevented the activation and maturation of DCs as well as the production of Th17 differentiation cytokines. DC conditioning by TSLP secreted from HCV-infected cells activated naïve CD4+ T lymphocytes, resulting in Th17 differentiation. Furthermore, we can detect substantial levels of hepatocyte TSLP in fibrotic liver tissue from chronic HCV patients. Thus, blockade of TSLP released by HCV-infected hepatocytes may suppress the induction/maintenance of hepatic Th17 responses and halt the progression of chronic liver disease to fibrosis and liver failure. CONCLUSION: Hepatocyte-derived TSLP conditions DCs to drive Th17 differentiation. Treatment of TSLP neutralizing antibody in HCV-infected hepatocyte/DC coculture abrogates DC conditioning and thereby inhibits Th17 differentiation.
UNLABELLED: Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. Here we report that infection of hepatic cells by HCV stimulates nuclear factor kappa B (NFκB)-dependent production of thymic stromal lymphopoietin (TSLP). Hepatocyte-derived TSLP in turn conditions dendritic cells (DCs) to drive T-helper (Th)17 differentiation. The TSLP secreted by HCV-infected hepatoma cells is capable of activating human monocyte-derived DCs by up-regulating the expression of CD40, CD86, CCL17, CCL22, and CCL20 which are activating markers of DCs. In addition, the production of key cytokines for Th17 differentiation, transforming growth factor beta (TGF-β), interleukin (IL)-6, and IL-21, is enhanced by human monocytes upon coculture with HCV-infected cells. Importantly, the blockade of TSLP using neutralizing antibody prevented the activation and maturation of DCs as well as the production of Th17 differentiation cytokines. DC conditioning by TSLP secreted from HCV-infected cells activated naïve CD4+ T lymphocytes, resulting in Th17 differentiation. Furthermore, we can detect substantial levels of hepatocyte TSLP in fibrotic liver tissue from chronic HCVpatients. Thus, blockade of TSLP released by HCV-infected hepatocytes may suppress the induction/maintenance of hepatic Th17 responses and halt the progression of chronic liver disease to fibrosis and liver failure. CONCLUSION: Hepatocyte-derived TSLP conditions DCs to drive Th17 differentiation. Treatment of TSLP neutralizing antibody in HCV-infected hepatocyte/DC coculture abrogates DC conditioning and thereby inhibits Th17 differentiation.
Authors: Deborah E Isaksen; Heinz Baumann; Baohua Zhou; Sebastien Nivollet; Andrew G Farr; Steven D Levin; Steven F Ziegler Journal: J Immunol Date: 2002-04-01 Impact factor: 5.422
Authors: J T Gerlach; H M Diepolder; M C Jung; N H Gruener; W W Schraut; R Zachoval; R Hoffmann; C A Schirren; T Santantonio; G R Pape Journal: Gastroenterology Date: 1999-10 Impact factor: 22.682
Authors: Catherine B Bigger; Bernadette Guerra; Kathleen M Brasky; Gene Hubbard; Michael R Beard; Bruce A Luxon; Stanley M Lemon; Robert E Lanford Journal: J Virol Date: 2004-12 Impact factor: 5.103
Authors: Andrew I Su; John P Pezacki; Lisa Wodicka; Amy D Brideau; Lubica Supekova; Robert Thimme; Stefan Wieland; Jens Bukh; Robert H Purcell; Peter G Schultz; Francis V Chisari Journal: Proc Natl Acad Sci U S A Date: 2002-11-19 Impact factor: 11.205
Authors: Salomé LeibundGut-Landmann; Olaf Gross; Matthew J Robinson; Fabiola Osorio; Emma C Slack; S Vicky Tsoni; Edina Schweighoffer; Victor Tybulewicz; Gordon D Brown; Jürgen Ruland; Caetano Reis e Sousa Journal: Nat Immunol Date: 2007-04-22 Impact factor: 25.606
Authors: David E Kaplan; Kazushi Sugimoto; Kimberly Newton; Mary E Valiga; Fusao Ikeda; Ayse Aytaman; Frederick A Nunes; Michael R Lucey; Barbara A Vance; Robert H Vonderheide; K Rajender Reddy; Jane A McKeating; Kyong-Mi Chang Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Fabio C O F Cachem; Aleida S Dias; Clarice Monteiro; José Roberto Castro; Gabriel Fernandes; Letícia Delphim; Adilson J Almeida; Felipe Tavares; Alessandra M A Maciel; Marcia M Amendola-Pires; Carlos E Brandão-Mello; Cleonice A M Bento Journal: Immunology Date: 2017-03-13 Impact factor: 7.397
Authors: Min Hyeok Jee; Ka Young Hong; Ji Hoon Park; Jae Seung Lee; Hee Sun Kim; Song Hee Lee; Sung Key Jang Journal: J Virol Date: 2015-12-30 Impact factor: 5.103
Authors: William R Proctor; Mala Chakraborty; Aaron M Fullerton; Midhun C Korrapati; Pauline M Ryan; Kenrick Semple; Jeffrey C Morrison; Julia D Berkson; Lynette S Chea; Qian Yang; Albert P Li; Rosanne Spolski; Erin E West; Yrina Rochman; Warren J Leonard; Mohammed Bourdi; Lance R Pohl Journal: Hepatology Date: 2014-05-20 Impact factor: 17.425
Authors: Celeste C Goh; Krystal M Roggerson; Hai-Chon Lee; Lucy Golden-Mason; Hugo R Rosen; Young S Hahn Journal: J Immunol Date: 2016-01-29 Impact factor: 5.422